Pfizer (PFE) EBT (2009 - 2026)

Pfizer (PFE) has reported EBT for 18 consecutive years, with -$653.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 121.45% year-over-year to -$653.0 million in Q2 2026; TTM through Jun 2026 was $4.2 billion, a 69.41% decrease from a year earlier, with the FY2025 full-year figure at $7.5 billion, down 6.27% from the prior year.
• EBT was -$653.0 million for Q2 2026 at Pfizer, down from $3.2 billion in the prior quarter.
• Over five years, EBT peaked at $11.4 billion in Q3 2022 and troughed at -$4.1 billion in Q4 2023.
• A 5-year average of $3.3 billion and a median of $3.1 billion in 2025 frame the typical range for EBT.
• Across the five-year window, EBT surged 3055.34% in 2025 and plunged 121.45% in 2026, its largest moves.
• Over 5 years, EBT stood at $11.4 billion in 2022, then slumped by 136.07% to -$4.1 billion in 2023, then surged by 294.55% to $8.0 billion in 2024, then sank by 120.44% to -$1.6 billion in 2025, then jumped by 60.23% to -$653.0 million in 2026.
• The last three EBT figures came in at -$653.0 million (Q2 2026), $3.2 billion (Q1 2026), and -$1.6 billion (Q4 2025), per Business Quant data.